Owlet Announces Strong Second Quarter 2024 Results, Achieves Record-Breaking Amazon Prime Day
Q2 2024 Financial Highlights:
-
Obtained CE Medical certification for
UK andEurope , launching Dream Sock across major European markets. -
Q2 Revenue was approximately
$20.7 million , up approximately 58% year over year. - Q2 Gross Margin was approximately 50%, up approximately 1,000 basis points year over year.
-
Q2 Net Loss was approximately
($1.1) million , improving approximately 85% compared to Net Loss of approximately($8.5) million year over year. -
Q2 adjusted EBITDA was approximately
$0.1 million compared to adjusted EBITDA loss of($4.3) million in the same prior year period.
“Owlet’s results in the first half of 2024 give us added confidence that this year is a turning point for our company. We have delivered strong, double-digit revenue and sell-through growth as we advance our vision to make Owlet the most trusted infant health monitoring ecosystem. Along with our excellent commercial progress, we have continued to streamline our business to achieve improved gross margins and significantly lower operating expenses, which in turn drove improved Adjusted EBITDA and a clear path to Adjusted EBITDA breakeven exiting 2024,” said
Workman continued, “While pleased with our advancements across our business, we are not resting and plan to continually lay the regulatory groundwork for additional commercial expansion in both our home US market and abroad. A prime example of this comes on the heels of our groundbreaking FDA clearances in 2023, and during the quarter, we announced medical certification and product introductions in both the
Financial Results for the Second Quarter Ended
Revenues for the second quarter of 2024 were approximately
Cost of revenues for the second quarter of 2024 was approximately
Operating expenses, including stock-based compensation, were approximately
Operating loss was approximately
Net loss was approximately
In the second quarter of 2024 there was a decrease in the fair value of common stock warrants outstanding, resulting in a gain of approximately
Adjusted EBITDA was approximately
Net loss per share was (
Financial Outlook
For the second half of 2024, we are estimating net revenue to be in the range of
For FY 2024, we are estimating net revenue to be in the range of
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expected financial performance, including the Company’s financial outlook, outlook based upon regulatory authorizations or product enhancements, growth prospects, and future operational efficiencies or results and expected market opportunity and acceptance. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made and are susceptible to a number of risks, uncertainties and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by our forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of
Disclosure Regarding Non-GAAP Financial Measures
In addition to the financial measures presented in this release in accordance with
The Company uses such non-GAAP financial measures as internal measures of business operating performance and as performance measures for benchmarking against the Company’s peers and competitors. The Company believes its presentation of EBITDA, adjusted EBITDA, adjusted net loss and adjusted net loss per share provide a meaningful perspective of the underlying operating performance of the Company’s current business and enables investors to better understand and evaluate its historical and prospective operating performance. The Company believes that these non-GAAP financial measures are important supplemental measures of operating performance because they exclude items that vary from period to period without correlation to the Company’s core operating performance and highlight trends in its business that may not otherwise be apparent when relying solely on GAAP financial measures. Due to the nature of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of the Company’s future operating performance. The Company believes investors, analysts and other interested parties use EBITDA, adjusted EBITDA, adjusted net loss and adjusted net loss per share in evaluating issuers, and the presentation of these measures facilitates a comparative assessment of the Company’s operating performance in addition to the Company’s performance based on GAAP results.
The Company’s non-GAAP financial measures should not be considered as an alternative to net loss or net loss per share as a measure of financial performance or any other performance measure derived in accordance with GAAP and should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items.
EBITDA is defined as net loss adjusted for income tax provision and interest expense, net and depreciation and amortization.
Adjusted EBITDA is defined as net loss adjusted for income tax provision, interest expense, interest expense from contingent beneficial conversion feature, interest income, depreciation and amortization, restructuring costs, warrant liability adjustments, gain on loan forgiveness, stock-based compensation, and transaction costs.
Adjusted net loss is defined as net loss adjusted for restructuring costs, common stock warrant liability adjustments, stock-based compensation, and transaction costs. Adjusted net loss per share is defined as adjusted net loss divided by the weighted-average shares of common stock outstanding.
EBITDA, adjusted EBITDA, adjusted net loss and adjusted net loss per share are not recognized terms under GAAP, and the Company’s presentation of these non-GAAP measures does not replace the presentation of the Company’s financial results in accordance with GAAP. Because all companies do not use EBITDA, adjusted EBITDA, adjusted net loss and adjusted net loss per share (and similarly titled financial measures) in the same way, those measures as used by other companies may not be consistent with the way the Company calculates such measures. The non-GAAP financial measures included in this release should not be construed as substitutes for or better indicators of the Company’s performance than the most directly comparable GAAP financial measures. See the reconciliation tables that accompany this release for additional information regarding certain of the non-GAAP financial measures included herein.
A reconciliation of the Company's guidance with respect to non-GAAP financial measures to the most directly comparable GAAP financial measure cannot be provided without unreasonable efforts and is not provided herein because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, the amounts of which could be material.
Conference Call and Webcast Information
Owlet will host a conference call and audio webcast today,
To access the conference call by telephone, please dial (833) 470-1428 (domestic) or +1 (404) 975-4839 (international) and reference Access Code 458341. To listen to the conference call via live audio webcast and access the accompanying presentation materials, please visit the Events section of Owlet’s Investor Relations website at investors.owletcare.com.
The archived webcast will also be available on Owlet’s Investor Relations website mentioned above.
About
Owlet’s digital health infant monitoring platform is transforming the journey of parenting. Owlet, a small-cap healthcare growth equity, offers FDA-authorized medical and consumer pediatric wearables and an integrated HD visual and audio camera that provide real-time data and insights to parents who safeguard health, optimize wellness, and ensure peaceful sleep, for their children.
Since 2012, over 2 million parents worldwide have used Owlet’s platform contributing to one of the largest collections of consumer infant health and sleep data. The Company continues to develop software and digital data solutions to bridge the current healthcare gap between hospital and home and bring new insights to parents and caregivers globally. Owlet believes that every child deserves to live a long, happy, and healthy life. To learn more, visit www.owletcare.com.
Source:
Condensed Consolidated Balance Sheets - Preliminary, Unaudited1 (in millions) |
||||||||
Assets |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
15.4 |
|
|
$ |
16.6 |
|
Accounts receivable, net |
|
|
16.9 |
|
|
|
14.0 |
|
Inventory |
|
|
8.1 |
|
|
|
6.5 |
|
Prepaid expenses and other current assets |
|
|
2.2 |
|
|
|
2.9 |
|
Total current assets |
|
|
42.5 |
|
|
|
39.9 |
|
Property and equipment, net |
|
|
0.2 |
|
|
|
0.4 |
|
Right of use assets, net |
|
|
0.2 |
|
|
|
0.9 |
|
Intangible assets, net |
|
|
2.2 |
|
|
|
2.2 |
|
Other assets |
|
|
0.7 |
|
|
|
0.7 |
|
Total assets |
|
$ |
45.9 |
|
|
$ |
44.1 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Accounts payable |
|
$ |
17.5 |
|
|
$ |
13.7 |
|
Accrued and other expenses |
|
|
11.6 |
|
|
|
15.1 |
|
Current portion of deferred revenues |
|
|
1.2 |
|
|
|
1.2 |
|
Line of credit |
|
|
9.7 |
|
|
|
9.3 |
|
Current portion of long-term debt |
|
|
2.1 |
|
|
|
5.9 |
|
Total current liabilities |
|
|
42.2 |
|
|
|
45.1 |
|
Common stock warrant liability |
|
|
24.4 |
|
|
|
27.8 |
|
Other long-term liabilities |
|
|
0.2 |
|
|
|
0.9 |
|
Total liabilities |
|
|
66.7 |
|
|
|
73.8 |
|
Total mezzanine equity |
|
|
12.6 |
|
|
|
7.9 |
|
Total stockholders’ equity |
|
|
(33.4 |
) |
|
|
(37.5 |
) |
Total liabilities and stockholders’ equity |
|
$ |
45.9 |
|
|
$ |
44.1 |
|
1 Amounts may not sum due to rounding |
Condensed Consolidated Statements of Cash Flows - Preliminary, Unaudited1 (in millions) |
|||||
|
For the Six Months Ended
|
||||
|
2024 |
|
|
2023 |
|
Net cash used in operating activities |
(6.7 |
) |
|
(16.8 |
) |
Net cash used in investing activities |
(0.1 |
) |
|
— |
|
Net cash provided by financing activities |
5.6 |
|
|
30.3 |
|
Net change in cash and cash equivalents |
(1.2 |
) |
|
13.5 |
|
1 Amounts may not sum due to rounding |
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - Preliminary, Unaudited1 (in millions, except share and per share amounts) |
|||||||||||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Revenues |
$ |
20.7 |
|
|
$ |
13.1 |
|
|
$ |
35.4 |
|
|
$ |
23.8 |
|
Cost of revenues |
|
10.4 |
|
|
|
7.9 |
|
|
|
18.7 |
|
|
|
14.4 |
|
Gross profit |
|
10.3 |
|
|
|
5.2 |
|
|
|
16.8 |
|
|
|
9.4 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
General and administrative |
|
6.3 |
|
|
|
6.1 |
|
|
|
12.3 |
|
|
|
15.0 |
|
Sales and marketing |
|
3.9 |
|
|
|
3.1 |
|
|
|
7.7 |
|
|
|
6.4 |
|
Research and development |
|
2.4 |
|
|
|
2.7 |
|
|
|
4.7 |
|
|
|
5.6 |
|
Total operating expenses |
|
12.5 |
|
|
|
11.9 |
|
|
|
24.8 |
|
|
|
27.1 |
|
Operating loss |
|
(2.2 |
) |
|
|
(6.7 |
) |
|
|
(8.0 |
) |
|
|
(17.7 |
) |
Other income (expense): |
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
— |
|
|
|
(0.1 |
) |
|
|
(0.1 |
) |
|
|
(2.9 |
) |
Common stock warrant liability adjustment |
|
1.0 |
|
|
|
(1.6 |
) |
|
|
10.2 |
|
|
|
0.3 |
|
Other income (expense), net |
|
0.1 |
|
|
|
(0.1 |
) |
|
|
0.1 |
|
|
|
(0.1 |
) |
Total other income (expense), net |
|
1.1 |
|
|
|
(1.7 |
) |
|
|
10.1 |
|
|
|
(2.7 |
) |
Income (loss) before income tax provision |
|
(1.1 |
) |
|
|
(8.5 |
) |
|
|
2.1 |
|
|
|
(20.3 |
) |
Income tax provision |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net income (loss) and comprehensive loss |
|
(1.1 |
) |
|
|
(8.5 |
) |
|
|
2.1 |
|
|
|
(20.3 |
) |
Accretion on convertible preferred stock |
|
(1.5 |
) |
|
|
(1.3 |
) |
|
|
(2.9 |
) |
|
|
(2.0 |
) |
Net income (loss) attributable to common stockholders |
|
(2.7 |
) |
|
|
(9.8 |
) |
|
|
(0.7 |
) |
|
|
(22.3 |
) |
Net loss per share attributable to common stockholders, basic and diluted |
$ |
(0.30 |
) |
|
$ |
(1.19 |
) |
|
$ |
(0.08 |
) |
|
$ |
(2.73 |
) |
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted |
|
8,867,399 |
|
|
|
8,213,247 |
|
|
|
8,803,729 |
|
|
|
8,162,102 |
|
1 Amounts may not sum due to rounding |
Reconciliation of GAAP to Non-GAAP Measures - Preliminary, Unaudited1 (in millions) |
||||||||||||||||
|
Three Months Ended
|
|
Six Months Ended
|
|||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|||||||||
Net income (loss) |
$ |
(1.1 |
) |
|
$ |
(8.5 |
) |
|
$ |
2.1 |
|
|
$ |
(20.3 |
) |
|
Income tax provision |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Interest expense, net |
|
— |
|
|
|
0.1 |
|
|
|
0.1 |
|
|
|
2.9 |
|
|
Depreciation and amortization |
|
0.1 |
|
|
|
0.2 |
|
|
|
0.2 |
|
|
|
0.5 |
|
|
EBITDA |
$ |
(1.0 |
) |
|
$ |
(8.2 |
) |
|
$ |
2.5 |
|
|
$ |
(16.9 |
) |
|
Common stock warrant liability adjustment |
|
(1.0 |
) |
|
|
1.6 |
|
|
|
(10.2 |
) |
|
|
(0.3 |
) |
|
Stock-based compensation |
|
2.1 |
|
|
|
2.6 |
|
|
|
4.3 |
|
|
|
5.4 |
|
|
Transaction costs |
|
0.1 |
|
|
|
(0.4 |
) |
|
|
0.4 |
|
|
|
1.7 |
|
|
Adjusted EBITDA |
$ |
0.1 |
|
|
$ |
(4.3 |
) |
|
$ |
(3.0 |
) |
|
$ |
(10.1 |
) |
|
1 Amounts may not sum due to rounding |
|
Three Months Ended
|
|
Six Months Ended
|
|||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
Net income (loss) |
$ |
(1.1 |
) |
|
$ |
(8.5 |
) |
|
$ |
2.1 |
|
|
$ |
(20.3 |
) |
|
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|||||||||
Common stock warrant liability adjustment |
|
(1.0 |
) |
|
|
1.6 |
|
|
|
(10.2 |
) |
|
|
(0.3 |
) |
|
Stock-based compensation |
|
2.1 |
|
|
|
2.6 |
|
|
|
4.3 |
|
|
|
5.4 |
|
|
Transaction costs |
|
0.1 |
|
|
|
(0.4 |
) |
|
|
0.4 |
|
|
|
1.7 |
|
|
Adjusted net income (loss) |
$ |
— |
|
|
$ |
(4.6 |
) |
|
$ |
(3.4 |
) |
|
$ |
(13.5 |
) |
|
Adjusted net income (loss) per share attributable to common stockholders |
$ |
— |
|
|
$ |
(0.56 |
) |
|
$ |
(0.38 |
) |
|
$ |
(1.65 |
) |
|
Weighted average number of shares outstanding |
|
8,867,399 |
|
|
|
8,213,247 |
|
|
|
8,803,729 |
|
|
|
8,162,102 |
|
|
1 Amounts may not sum due to rounding |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812963145/en/
Investor:
ICR Westwicke
Phone: +1.617.877.9641
mike.cavanaugh@westwicke.com
Media:
pr@owletcare.com
Source: